NASDAQ:POAI Predictive Oncology (POAI) Stock Price, News & Analysis $1.11 +0.01 (+0.91%) Closing price 03/21/2025 04:00 PM EasternExtended Trading$1.11 0.00 (0.00%) As of 03/21/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends About Predictive Oncology Stock (NASDAQ:POAI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Predictive Oncology alerts:Sign Up Key Stats Today's Range$1.05▼$1.1450-Day Range$1.07▼$1.9552-Week Range$0.55▼$3.06Volume80,483 shsAverage Volume1.70 million shsMarket Capitalization$7.60 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingHold Company OverviewPredictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.Read More… Remove Ads Predictive Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScorePOAI MarketRank™: Predictive Oncology scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingPredictive Oncology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePredictive Oncology has received no research coverage in the past 90 days.Read more about Predictive Oncology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Predictive Oncology are expected to grow in the coming year, from ($2.08) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Predictive Oncology is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Predictive Oncology is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPredictive Oncology has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Predictive Oncology's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.23% of the float of Predictive Oncology has been sold short.Short Interest Ratio / Days to CoverPredictive Oncology has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Predictive Oncology has recently increased by 10.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPredictive Oncology does not currently pay a dividend.Dividend GrowthPredictive Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.23% of the float of Predictive Oncology has been sold short.Short Interest Ratio / Days to CoverPredictive Oncology has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Predictive Oncology has recently increased by 10.62%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.78 News SentimentPredictive Oncology has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Predictive Oncology this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for POAI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Predictive Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.44% of the stock of Predictive Oncology is held by insiders.Percentage Held by InstitutionsOnly 9.04% of the stock of Predictive Oncology is held by institutions.Read more about Predictive Oncology's insider trading history. Receive POAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address POAI Stock News HeadlinesPredictive Oncology completes sale of Skyline Medical assets to DeRoyalMarch 21 at 11:39 AM | markets.businessinsider.comPredictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal IndustriesMarch 20 at 7:00 AM | globenewswire.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…March 23, 2025 | Crypto Swap Profits (Ad)Predictive Oncology moves to finalize merger agreement with RenovaroMarch 3, 2025 | markets.businessinsider.comRenovaro completes first milestone payment for Predictive Oncology dealMarch 3, 2025 | markets.businessinsider.comPredictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro BiosciencesMarch 3, 2025 | finance.yahoo.comPredictive Oncology Closes Registered Direct OfferingFebruary 19, 2025 | globenewswire.comPredictive Oncology prices 363,336 shares at $1.50 in registered direct offeringFebruary 19, 2025 | markets.businessinsider.comSee More Headlines POAI Stock Analysis - Frequently Asked Questions How have POAI shares performed this year? Predictive Oncology's stock was trading at $0.82 at the beginning of 2025. Since then, POAI shares have increased by 35.4% and is now trading at $1.11. View the best growth stocks for 2025 here. How were Predictive Oncology's earnings last quarter? Predictive Oncology Inc. (NASDAQ:POAI) issued its quarterly earnings results on Tuesday, May, 14th. The medical instruments supplier reported ($1.04) EPS for the quarter. The medical instruments supplier had revenue of $0.42 million for the quarter. Predictive Oncology had a negative trailing twelve-month return on equity of 286.30% and a negative net margin of 1,012.32%. When did Predictive Oncology's stock split? Predictive Oncology shares reverse split on Monday, April 24th 2023. The 1-20 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Predictive Oncology? Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Predictive Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Predictive Oncology investors own include Ford Motor (F), Wells Fargo & Company (WFC), Zomedica (ZOM), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Bank of America (BAC) and Wayfair (W). Company Calendar Last Earnings5/14/2024Today3/23/2025Next Earnings (Estimated)3/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:POAI CIK1446159 Webwww.precisiontherapeutics.com Phone(651) 389-4800FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+170.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,980,000.00 Net Margins-1,012.32% Pretax Margin-983.62% Return on Equity-286.30% Return on Assets-122.11% Debt Debt-to-Equity RatioN/A Current Ratio1.20 Quick Ratio1.06 Sales & Book Value Annual Sales$1.48 million Price / Sales5.12 Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book0.54Miscellaneous Outstanding Shares6,846,000Free Float6,438,000Market Cap$7.60 million OptionableNot Optionable Beta1.22 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:POAI) was last updated on 3/23/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Predictive Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Predictive Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.